Merck Research Site Debate
Full Debate: Read Full DebateDepartment: Department for Energy Security & Net Zero
Lord Leong
Main Page: Lord Leong (Labour - Life peer)Department Debates - View all Lord Leong's debates with the Department for Energy Security & Net Zero
(1 day, 15 hours ago)
Lords ChamberRead Full debate Read Hansard Text Watch Debate Read Debate Ministerial Extracts
Lord Johnson of Lainston (Con)
Would the Minister follow up my noble friend’s comment—
Lord in Waiting/Government Whip (Lord Leong) (Lab)
Sorry, my Lords, but the noble Lord was not present at the start of this debate.
Lord Johnson of Lainston (Con)
I am sorry, but I was actually in the doorway, coming in. I would be grateful if I could ask the question, if that is possible. My noble friend Lord Markham raised an important point about the Treasury’s view of how these pricing processes function. The reality is that if we do not have the drug companies in this country, we are not just going to miss the opportunity for investment, we will lose the opportunity for clinical trials for our patients and individuals in the NHS to get access to these new medicines. I return to the question about an assessment of the overall cost of these measures and a proper assessment of the understanding of how investment from the biopharma sector in the UK actually adds up, not just in relation to the pounds, shillings and pence of the medicines.